Cathie Wood drops $1.3 million on healthcare stock

Core Insights - Cathie Wood's investment strategy focuses on transformative technologies, particularly in the field of gene editing, which she views as a significant market-changing opportunity [1][3]. Company and Industry Summary - ARK Invest has been actively purchasing shares of CRISPR Therapeutics, indicating a strong commitment to the long-term potential of gene editing technology [2][4]. - CRISPR Therapeutics specializes in gene editing, a technology that is compared to the early days of the internet in terms of its potential to revolutionize industries [3][8]. - The recent trading activity included the acquisition of over 76,800 shares of CRISPR in just three trading days, demonstrating a significant investment in the company [6][8]. - The total investment in CRISPR during this period amounted to over $4.4 million, reflecting a strategic doubling down on a long-term vision for the biotech sector [5][7]. - CRISPR Therapeutics is still in an early-commercial phase, which presents a unique investment profile as it is not strictly pre-revenue but still not fully established in terms of profitability [10].